New Alzheimer's Drug Repairs DNA Damage and Reduces Brain Inflammation
Alzheimer's Disease
Summary
Researchers have identified KCL-286, a drug originally developed for spinal cord injuries, as a promising candidate for Alzheimer's treatment. In mouse studies, the drug repaired dangerous DNA damage, reduced brain inflammation, and addressed multiple disease pathways beyond just amyloid and tau proteins. Since KCL-286 has already passed initial human safety testing, scientists believe it could advance more rapidly into clinical trials for Alzheimer's patients, offering a novel multi-targeted approach to this progressive neurodegenerative disease.
